Myovant Sciences (MYOV), a healthcare company committed to the creation of groundbreaking therapies for female prostate health and cancer, announced today that the 37th Annual J.P. Morgan Healthcare Conference will take place on Wednesday 15th January 2020 at 07:30 a.m. Myovant Sciences Chairman, Myovant, M.D. San Francisco, California, Pacific Time.
A live webcast will be made available on the Events website at www.myovant.com under the Investors&Media domain. Please ensure that the time is sufficient for any software download needed for listening to the webcast, please log in to the company website at least 15 minutes before the presentation. The webcast is replayed for 30 days after the conference at the same location.
About Myovant Sciences
As a scientifically based biopharmaceutical corporation, Myovant Sciences Ltd. operates. Innovatory therapies for the wellbeing of women and other endocrine-related disorders are developed and sold by the Company. Myovant Sciences develops relugolix for uterine fibroids and endometriosis-associated pain to treat excessive menstrual bleeding.
Myovant Sciences is a groundbreaking women’s health and prostate cancer care business that aims at being the leading health company. Relugolix, a one-day oral GnRH receiver antagonist, is the main product candidate for the business. The company has three clinical late-stage programs in uterine fibroids, endometriosis and prostate cancer for relugolix. The company also produced MVT-602, a Phase 2a trial for women’s infertility as part of assisted reproduction, a kisspeptin-1 receptor oligopeptide agonist. The company has been given an exclusive worldwide license to develop and sell (excluding Japan and certain other Asian countries), and an exclusive license to develop and market MVT-602 in every country worldwide by Takeda Pharmaceutical International AG, a subsidiary of the Takeda Pharmaceutical Company Limited.
Myovant Sciences leading research candidate for medicines is GnRH-receptor relugolix, a small molecule. We have five multinational clinical trials in phase 3, two of which are in females having high-menstrual fibroid-related bleeding (LIBERTY 1 & 2), and two in females with endometriosis-related pain (SPIRIIT 1 & 2), and one of which is in males with high-progressed prostate cancer (HERO).